Report Detail

Request for Sample of this report

Pharma & Healthcare Global Short-acting Insulin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

  • RnM4771910
    • |
  • 06 November, 2026
    • |
  • Global
    • |
  • 125 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Short-acting Insulin market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Short-acting insulin is a type of insulin that is designed to have a rapid onset and relatively short duration of action in the body.It is used to control blood Short-acting insulin is a type of insulin that is designed to have a rapid onset and relatively short duration of action in the body.This type of insulin starts working within about 15 to 30 minutes after injection,and continues to lower blood sugar for approximately 3 to 6 hours.Its primary function is to manage blood sugar levels by facilitating the uptake of glucose into cells.
This report is a detailed and comprehensive analysis for global Short-acting Insulin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Short-acting Insulin market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Short-acting Insulin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Short-acting Insulin market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Short-acting Insulin market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Short-acting Insulin
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Short-acting Insulin market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Novo Nordisk, Biocon Biologics, Sanofi, Wockhardt, Bayer, Pfizer, BASF, Abbott Laboratories, Tonghua Dongbao Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Short-acting Insulin market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Regular Insulin
Biosynthetic Human Insulin
Recombinant Human Insulin
Other
Market segment by Application
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Complications of Diabetes
Other
Major players covered
Eli Lilly
Novo Nordisk
Biocon Biologics
Sanofi
Wockhardt
Bayer
Pfizer
BASF
Abbott Laboratories
Tonghua Dongbao Pharmaceutical
Zhuhai United Pharmaceutical
Sinovac Biotech
Wanbang Biopharmaceuticals
HTBT
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Short-acting Insulin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Short-acting Insulin, with price, sales quantity, revenue, and global market share of Short-acting Insulin from 2021 to 2026.
Chapter 3, the Short-acting Insulin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Short-acting Insulin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Short-acting Insulin market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Short-acting Insulin.
Chapter 14 and 15, to describe Short-acting Insulin sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Short-acting Insulin Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Regular Insulin
    • 1.3.3 Biosynthetic Human Insulin
    • 1.3.4 Recombinant Human Insulin
    • 1.3.5 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Short-acting Insulin Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Type 1 Diabetes
    • 1.4.3 Type 2 Diabetes
    • 1.4.4 Gestational Diabetes
    • 1.4.5 Complications of Diabetes
    • 1.4.6 Other
  • 1.5 Global Short-acting Insulin Market Size & Forecast
    • 1.5.1 Global Short-acting Insulin Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Short-acting Insulin Sales Quantity (2021-2032)
    • 1.5.3 Global Short-acting Insulin Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Eli Lilly
    • 2.1.1 Eli Lilly Details
    • 2.1.2 Eli Lilly Major Business
    • 2.1.3 Eli Lilly Short-acting Insulin Product and Services
    • 2.1.4 Eli Lilly Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Eli Lilly Recent Developments/Updates
  • 2.2 Novo Nordisk
    • 2.2.1 Novo Nordisk Details
    • 2.2.2 Novo Nordisk Major Business
    • 2.2.3 Novo Nordisk Short-acting Insulin Product and Services
    • 2.2.4 Novo Nordisk Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Novo Nordisk Recent Developments/Updates
  • 2.3 Biocon Biologics
    • 2.3.1 Biocon Biologics Details
    • 2.3.2 Biocon Biologics Major Business
    • 2.3.3 Biocon Biologics Short-acting Insulin Product and Services
    • 2.3.4 Biocon Biologics Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Biocon Biologics Recent Developments/Updates
  • 2.4 Sanofi
    • 2.4.1 Sanofi Details
    • 2.4.2 Sanofi Major Business
    • 2.4.3 Sanofi Short-acting Insulin Product and Services
    • 2.4.4 Sanofi Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Sanofi Recent Developments/Updates
  • 2.5 Wockhardt
    • 2.5.1 Wockhardt Details
    • 2.5.2 Wockhardt Major Business
    • 2.5.3 Wockhardt Short-acting Insulin Product and Services
    • 2.5.4 Wockhardt Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Wockhardt Recent Developments/Updates
  • 2.6 Bayer
    • 2.6.1 Bayer Details
    • 2.6.2 Bayer Major Business
    • 2.6.3 Bayer Short-acting Insulin Product and Services
    • 2.6.4 Bayer Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Bayer Recent Developments/Updates
  • 2.7 Pfizer
    • 2.7.1 Pfizer Details
    • 2.7.2 Pfizer Major Business
    • 2.7.3 Pfizer Short-acting Insulin Product and Services
    • 2.7.4 Pfizer Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Pfizer Recent Developments/Updates
  • 2.8 BASF
    • 2.8.1 BASF Details
    • 2.8.2 BASF Major Business
    • 2.8.3 BASF Short-acting Insulin Product and Services
    • 2.8.4 BASF Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 BASF Recent Developments/Updates
  • 2.9 Abbott Laboratories
    • 2.9.1 Abbott Laboratories Details
    • 2.9.2 Abbott Laboratories Major Business
    • 2.9.3 Abbott Laboratories Short-acting Insulin Product and Services
    • 2.9.4 Abbott Laboratories Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Abbott Laboratories Recent Developments/Updates
  • 2.10 Tonghua Dongbao Pharmaceutical
    • 2.10.1 Tonghua Dongbao Pharmaceutical Details
    • 2.10.2 Tonghua Dongbao Pharmaceutical Major Business
    • 2.10.3 Tonghua Dongbao Pharmaceutical Short-acting Insulin Product and Services
    • 2.10.4 Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
  • 2.11 Zhuhai United Pharmaceutical
    • 2.11.1 Zhuhai United Pharmaceutical Details
    • 2.11.2 Zhuhai United Pharmaceutical Major Business
    • 2.11.3 Zhuhai United Pharmaceutical Short-acting Insulin Product and Services
    • 2.11.4 Zhuhai United Pharmaceutical Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Zhuhai United Pharmaceutical Recent Developments/Updates
  • 2.12 Sinovac Biotech
    • 2.12.1 Sinovac Biotech Details
    • 2.12.2 Sinovac Biotech Major Business
    • 2.12.3 Sinovac Biotech Short-acting Insulin Product and Services
    • 2.12.4 Sinovac Biotech Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Sinovac Biotech Recent Developments/Updates
  • 2.13 Wanbang Biopharmaceuticals
    • 2.13.1 Wanbang Biopharmaceuticals Details
    • 2.13.2 Wanbang Biopharmaceuticals Major Business
    • 2.13.3 Wanbang Biopharmaceuticals Short-acting Insulin Product and Services
    • 2.13.4 Wanbang Biopharmaceuticals Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Wanbang Biopharmaceuticals Recent Developments/Updates
  • 2.14 HTBT
    • 2.14.1 HTBT Details
    • 2.14.2 HTBT Major Business
    • 2.14.3 HTBT Short-acting Insulin Product and Services
    • 2.14.4 HTBT Short-acting Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 HTBT Recent Developments/Updates

3 Competitive Environment: Short-acting Insulin by Manufacturer

  • 3.1 Global Short-acting Insulin Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Short-acting Insulin Revenue by Manufacturer (2021-2026)
  • 3.3 Global Short-acting Insulin Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Short-acting Insulin by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Short-acting Insulin Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Short-acting Insulin Manufacturer Market Share in 2025
  • 3.5 Short-acting Insulin Market: Overall Company Footprint Analysis
    • 3.5.1 Short-acting Insulin Market: Region Footprint
    • 3.5.2 Short-acting Insulin Market: Company Product Type Footprint
    • 3.5.3 Short-acting Insulin Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Short-acting Insulin Market Size by Region
    • 4.1.1 Global Short-acting Insulin Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Short-acting Insulin Consumption Value by Region (2021-2032)
    • 4.1.3 Global Short-acting Insulin Average Price by Region (2021-2032)
  • 4.2 North America Short-acting Insulin Consumption Value (2021-2032)
  • 4.3 Europe Short-acting Insulin Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Short-acting Insulin Consumption Value (2021-2032)
  • 4.5 South America Short-acting Insulin Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Short-acting Insulin Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Short-acting Insulin Sales Quantity by Type (2021-2032)
  • 5.2 Global Short-acting Insulin Consumption Value by Type (2021-2032)
  • 5.3 Global Short-acting Insulin Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Short-acting Insulin Sales Quantity by Application (2021-2032)
  • 6.2 Global Short-acting Insulin Consumption Value by Application (2021-2032)
  • 6.3 Global Short-acting Insulin Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Short-acting Insulin Sales Quantity by Type (2021-2032)
  • 7.2 North America Short-acting Insulin Sales Quantity by Application (2021-2032)
  • 7.3 North America Short-acting Insulin Market Size by Country
    • 7.3.1 North America Short-acting Insulin Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Short-acting Insulin Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Short-acting Insulin Sales Quantity by Type (2021-2032)
  • 8.2 Europe Short-acting Insulin Sales Quantity by Application (2021-2032)
  • 8.3 Europe Short-acting Insulin Market Size by Country
    • 8.3.1 Europe Short-acting Insulin Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Short-acting Insulin Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Short-acting Insulin Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Short-acting Insulin Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Short-acting Insulin Market Size by Region
    • 9.3.1 Asia-Pacific Short-acting Insulin Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Short-acting Insulin Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Short-acting Insulin Sales Quantity by Type (2021-2032)
  • 10.2 South America Short-acting Insulin Sales Quantity by Application (2021-2032)
  • 10.3 South America Short-acting Insulin Market Size by Country
    • 10.3.1 South America Short-acting Insulin Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Short-acting Insulin Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Short-acting Insulin Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Short-acting Insulin Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Short-acting Insulin Market Size by Country
    • 11.3.1 Middle East & Africa Short-acting Insulin Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Short-acting Insulin Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Short-acting Insulin Market Drivers
  • 12.2 Short-acting Insulin Market Restraints
  • 12.3 Short-acting Insulin Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Short-acting Insulin and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Short-acting Insulin
  • 13.3 Short-acting Insulin Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Short-acting Insulin Typical Distributors
  • 14.3 Short-acting Insulin Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Short-acting Insulin. Industry analysis & Market Report on Short-acting Insulin is a syndicated market report, published as Global Short-acting Insulin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Short-acting Insulin market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo